Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ11 | Q14654 | 18/20 | 0.66 |
| ▸ | ABCC9 | O60706 | 8/20 | 0.60 |
| ▸ | ABCC8 | Q09428 | 8/20 | 0.60 |
| ▸ | KCNJ8 | Q15842 | 8/20 | 0.60 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117140 | 0.81 | KCNJ11 (0.76) | KCNJ11ABCC9ABCC8KCNJ8 | |
| SCHEMBL7112062 | 0.80 | KCNJ11 (0.72) | KCNJ11ABCC9ABCC8KCNJ8 | |
| SCHEMBL7116176 | 0.80 | KCNJ11 (1.00) | KCNJ11ABCC9ABCC8KCNJ8 | |
| SCHEMBL31490630 | 0.78 | MAPT (0.51) | ALDH1A1MAPTHPGD | |
| SCHEMBL5565461 | 0.77 | MAPT (0.48) | ALDH1A1MAPTHPGD | |
| SCHEMBL7112057 | 0.77 | MAPT (0.63) | KCNJ11ABCC9ABCC8KCNJ8PDK1 | |
| SCHEMBL7114326 | 0.77 | KCNJ11 (0.67) | KCNJ11ABCC9ABCC8KCNJ8 | |
| SCHEMBL7120313 | 0.77 | KCNJ11 (0.67) | KCNJ11ABCC9ABCC8KCNJ8PDK1 | |
| SCHEMBL29405861 | 0.75 | KCNJ11 (1.00) | KCNJ11ABCC9ABCC8KCNJ8 | |
| SCHEMBL4260449 | 0.75 | KCNJ11 (1.00) | KCNJ11ABCC9ABCC8KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003089404-A1 | NAPHTHALENE AMIDES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2003-10-30 | — | — | WO | claimed |
| US-20030199578-A1 | Naphthalene amides as potassium channel openers | ABBOTT LABORATORIES | 2003-10-23 | — | — | US | claimed |
| WO-2003089404-A1 | NAPHTHALENE AMIDES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2003-10-30 | — | — | WO | disclosed |
| US-20030199578-A1 | Naphthalene amides as potassium channel openers | ABBOTT LABORATORIES | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199578-A1 | Naphthalene amides as potassium channel openers | KCNJ2, KCNN2, KCNJ1 | KCNJ11 11/4885ABCC9 264/4885ABCC8 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.